Feasibility and safety of PIPAC combined with additional surgical procedures: PLUS study.
暂无分享,去创建一个
A. Nissan | M. Pocard | O. Sgarbura | P. Piso | J. Gagnière | C. Eveno | P. Berchialla | M. Vaira | M. Reymond | J. Torkington | C. Soravia | A. Kaprin | J. Coget | G. Vizzielli | A. Brandl | F. Dumont | W. Ceelen | O. Glehen | K. Lehmann | T. Jäger | J. Abba | L. Villeneuve | M. Alyami | I. D. de Hingh | M. Hubner | A. Bhatt | J. Galindo | D. Cortés-Guiral | T. Glatz | V. Kepenekian | W. Willaert | S. P. Somashekhar | C. Lynch | G. O. Pérez | J. Delhorme | Cecilia Escayola | M. Robella | S. Mehta | A. Ezanno | V. Khomiakov | A. di Giorgio | Naoual Bakrin | Maciej Nowacki | Adnane Afifi | T. Courvoiser | K. Kothonidis | D. Orry | B. Paquette | M. Paškonis | B. Rau | Abelkader Taibi | S. Singh | H. Teixeira | F. Ferracci | J. So | M. B. Mortensen | Guillaume De Meeus | B. Moldovan | Shivendra P Singh | C. Escayola | I. D. de Hingh | G. Vizzielli
[1] A. Nissan,et al. Consensus guidelines for pressurized intraperitoneal aerosol chemotherapy: Technical aspects and treatment protocols. , 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[2] J. Funder,et al. The impact of postoperative complications following cytoreductive surgery combined with oxaliplatin based heated intraperitoneal chemotherapy. , 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[3] R. Cavalli,et al. A Phase I Dose Escalation Study of Oxaliplatin, Cisplatin and Doxorubicin Applied as PIPAC in Patients with Peritoneal Carcinomatosis , 2021, Cancers.
[4] B. Goh,et al. PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases , 2020, Clinical Cancer Research.
[5] O. Sgarbura,et al. Current practice of pressurized intraperitoneal aerosol chemotherapy (PIPAC): Still standardized or on the verge of diversification? , 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[6] A. Pisacane,et al. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Oxaliplatin, Cisplatin, and Doxorubicin in Patients with Peritoneal Carcinomatosis: An Open-Label, Single-Arm, Phase II Clinical Trial , 2020, Biomedicines.
[7] L. Lundell,et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) of peritoneal metastasis from gastric cancer: a descriptive cohort study , 2020, Clinical & Experimental Metastasis.
[8] E. Decullier,et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) might increase the risk of anastomotic leakage compared to HIPEC: an experimental study , 2019, Surgical Endoscopy.
[9] M. Hübner,et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. , 2019, The Lancet. Oncology.
[10] R. Cavalli,et al. Exploring the Use of Pegylated Liposomal Doxorubicin (Caelyx®) as Pressurized Intraperitoneal Aerosol Chemotherapy , 2019, Front. Pharmacol..
[11] C. Meisner,et al. Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C/D) in patients with gastric cancer and peritoneal metastasis: a phase II study , 2019, Therapeutic advances in medical oncology.
[12] M. Pocard,et al. Phase I/II study of oxaliplatin dose escalation via a laparoscopic approach using pressurized aerosol intraperitoneal chemotherapy (PIPOX trial) for nonresectable peritoneal metastases of digestive cancers (stomach, small bowel and colorectal): Rationale and design , 2018, Pleura and peritoneum.
[13] C. Tempfer,et al. How to Perform Safe and Technically Optimized Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): Experience After a Consecutive Series of 1200 Procedures , 2018, Journal of Gastrointestinal Surgery.
[14] C. Tempfer,et al. A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis. , 2018, Gynecologic oncology.
[15] C. Tempfer,et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal carcinomatosis: systematic review of clinical and experimental evidence with special emphasis on ovarian cancer , 2018, Archives of Gynecology and Obstetrics.
[16] M. Pocard,et al. Intraperitoneal aerosolization of albumin-stabilized paclitaxel nanoparticles (Abraxane™) for peritoneal carcinomatosis – a phase I first-in-human study , 2018, Pleura and peritoneum.
[17] O. Sgarbura,et al. Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[18] N. Demartines,et al. Pressurized IntraPeritoneal Aerosol Chemotherapy - Practical aspects. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[19] N. Demartines,et al. Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis , 2017, The British journal of surgery.
[20] M. Vaira,et al. Single-port access for Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC): technique, feasibility and safety , 2016, Pleura and peritoneum.
[21] V. Lemmens,et al. Short-term outcome in patients treated with cytoreduction and HIPEC compared to conventional colon cancer surgery , 2016, Medicine.
[22] M. Vaira,et al. Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis , 2016, World Journal of Surgical Oncology.
[23] W. Solass,et al. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis , 2016, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.
[24] W. Solass,et al. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis , 2015, Journal of Gastrointestinal Surgery.
[25] W. Solass,et al. Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: A phase 2 study. , 2015, Gynecologic oncology.
[26] Urs Giger-Pabst,et al. Intraperitoneal Chemotherapy of Peritoneal Carcinomatosis Using Pressurized Aerosol as an Alternative to Liquid Solution: First Evidence for Efficacy , 2013, Annals of Surgical Oncology.
[27] W. Solass,et al. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): Occupational Health and Safety Aspects , 2013, Annals of Surgical Oncology.
[28] F. Zoetmulder,et al. Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei--a report of 103 procedures. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[29] H. Tinteren,et al. Toxicity of cytoreductive surgery and hyperthermic intra‐peritoneal chemotherapy , 2004, Journal of surgical oncology.